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INTRODUCTION
Focal cerebral ischemia elicits various types of neuronal injuries 
including neurodegeneration, motor dysfunction and cognitive 
impairment. Necrosis takes place in neurons and supporting 
glia because of severe oxygen and glucose shortage [1, 2]. The 
penumbra is at the peripheral zone of this core injury and can 
be salvageable if collateral arteries provide blood into this region 
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Albumin is known to have neuroprotective effects. The protein has a long half-life circulation, and its effects can therefore persist for 
a long time to aid in the recovery of brain ischemia. In the present study, we investigated the neuroprotective effects of human serum 
albumin (HSA) on brain hemodynamics. Albumin is administrated using repeated oral gavage to the rodents. Sprague-Dawley 
rats underwent middle cerebral artery occlusion procedures and served as a stroke model. Afterwards, 25% human serum albumin 
(1.25 g/kg) or saline (5 ml/kg) was orally administrated for 2 weeks in alternating days. After 2 weeks, the rodents were assessed for 
levels of brain ischemia. Our testing battery consists of behavioral tests and in vivo optical imaging sessions. Modified neurological 
severity scores (mNSS) were obtained to assess the levels of ischemia and the effects of HSA oral administration. We found that the 
experimental group demonstrated larger hemodynamic responses following sensory stimulation than controls that were adminis-
tered with saline. HSA administration resulted in more significant changes in cerebral blood volume following direct cortical electric 
stimulation. In addition, the mNSS of the treatment group was lower than the control group. In particular, brain tissue staining re-
vealed that the infarct size was also much smaller with HSA administration. This study provides support for the efficacy of HSA, and 
that long-term oral administration of HSA may induce neuroprotective effects against brain ischemia.
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[3]. However, if the blockage of the main cerebral artery persists, 
penumbral cells will undergo necrosis. The clinical point of stroke 
intervention is to improve neuronal injury and reduce the effects 
of ischemia. Once neural cells get damaged, recovery is difficult, 
therefore it is important to protect ischemic situations during 
stroke. 
Human serum albumin (HSA) is produced in the liver and has 
multifunctional roles [4]. HSA is soluble and a monomeric hu-
man protein that transports hormones, free fatty acids and other 
compounds. It also works as a pH buffer and maintains osmotic 
pressure [5]. The role of albumin in neuroprotection has been 
studied over many years [6]. Much research have demonstrated 
the effectiveness of albumin administration in diminishing brain 
infarction volumes and brain edema, as well as compromise blood 
brain barrier permeability [7-9]. HSA also specifically inhibits 
endothelial cell apoptosis and histopathological damages [10, 
11]. High-dose albumin therapy ameliorates neurological func-
tion and improves the reduced local perfusion of blood flow in 
the ischemic brain [12]. HSA is typically administered through 
intravenous injection (I.V.); although I.V injection is a direct and 
effective way of delivering materials into the body, it requires the 
use of needles. Thus, if oral administration of HSA is evinced to 
bring about similar protection effects as I.V. injections, then it can 
be developed into a more generalized intervention that can be ap-
plied to individuals of all ages. 
In our previous study, we have shown that optical recordings of 
intrinsic signals (ORIS) can be utilized to monitor hemodynamic 
alterations in a MCAO model. We reported that the hemodynam-
ic response of the ischemia region to electrical stimulation was 
drastically decreased, and ORIS measurements were tightly cor-
related with the severity of ischemia [13]. ORIS is a relatively easy 
technique to assess the levels of cerebral perfusion and is readily 
applicable to monitor the effects of HSA oral administration. 
MATERIALS AND METHODS
Animal preparation for surgical and experimental procedures
All surgical procedures followed the guidelines of Sungkyunk-
wan University IACUC (SKKUIACUC). Male Sparque-Dewley 
rats (n=14, 280~310 g) were used for the study. Animals were anes-
thetized with isoflurane (3% induction of anesthesia; 2% mainte-
nance during experiment) and laid on the bed with paper towels. 
Body temperatures were maintained hot pads. The surgical and 
experimental procedures were performed under said conditions.
Procedure for middle cerebral artery occlusion (MCAO)
The animals’ bodies were fixed on the stereotaxic frame. A 0.5 
mm incision was made on the right side of the midline neck to 
search and expose the external carotid artery (ECA), internal ca-
rotid artery (ICA) and common carotid artery (CCA). These three 
vessels were isolated from the tissue along with other muscles. The 
isolated vessels from the tissue were tied in the order of ECA, CCA 
and ICA with silk sutures. In order to insert the suture, the punc-
ture was made above the knot of arteries. A 4-0 monofilament 
suture that with a poly-L-lysine coated tip was inserted 20 mm via 
the ICA into the right middle cerebral artery (MCA) (standard 
length insertion for a 300 g animal). The incision was then stitched 
up. The right MCA was occluded for 90 minutes, after which the 
animals were again anesthetized for reperfusion of MCA and re-
opening of the sealed incision. After the tail of the suture was 
searched, the suture was carefully pulled from the MCA and the 
remaining suture head, which is coated with poly-L-lysine, was left 
inside the ICA. When this process was over, incision was stitched 
up again and animals were put back to their cages.
Oral administration of albumin and saline
Animals of the MCAO model were divided into two groups, 
one group received human serum albumin (HSA) solution (25%, 
1.25 g/kg, n=7) and another group received saline (0.9% isotonic 
sodium chloride solution, 5 ml/kg, n=7). The HSA solution was 
prepared by dissolving powdered HSA in saline. Each animal of 
the two groups were started on oral administration of either HSA 
or saline 3 hours after the onset of stroke. To alleviate animal suf-
fering from MCAO surgery and the stress from oral dosing pro-
cedures, oral administration was only given on alternate days for 
2 weeks. For oral gavages, a flexible feeding needle (Jeungdo bio, 
Korea) was used. Proper length of feeding needles was applied to 
each animal according to the animal’s weight.
Neurological behavioral tests
Behavioral tests were performed for each animal from the two 
groups; animals were selected blindly for the behavioral tests. We 
graded the level of sensory motor deficits following days 1, 7 and 
14 post-surgery. Modified neurological severity scores (mNSS) [14] 
were used for assessing sensory-motor deficits. A normal score 
was represented by 0 and the maximal deficit score was 14.
Optical recording of intrinsic signal (ORIS) and electrical 
stimulation
Fourteen days after the MCAO procedure, animals were pre-
pared for ORIS recordings of the sensory cortex. Animals were 
initially anesthetized by inhalation with 3% isoflurane for induc-
tion and craniotomy and 2% isoflurane for maintenance during 
the experiment. Animals were laid on the bed with paper towels, 
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with a hot pad to keep body temperature stable. Their heads were 
fixed on stereotaxic frames, and the skin over their sensory cortex 
was cut and cranial bones were exposed. The skull from the breg-
ma to lambda (4 mm×4 mm) was carefully removed with a dental 
drill to expose the dura mater. Exposed brain tissue was illumi-
nated evenly using a halogen lamp. Direct electrical stimulation 
(biphasic, 1 mA, 3 Hz) was given to the brain tissue with a bipolar 
electrode (Plastic One, Roanoke, VA). The stimulation started 30 
seconds following ORIS recording and lasted for 10 seconds. Im-
ages were simultaneously acquired with a CCD camera (Ademic, 
Netherlands) at 3.33 Hz through 570 nm band-pass filter, the 
wavelength at which cerebral blood volume is sensitive to. This 
stimulation elicited cerebral blood volume changes. The whole 
recording time was 300 seconds and data were analyzed with a 
program written in MATLAB.
Data analysis
Acquired images from the ORIS system were analyzed with a 
program written in MATLAB for calculating changes in cerebral 
blood volume. The frames during the initial 30 seconds before 
electrical stimulation were taken as baseline and the remaining 
frames were then normalized to this baseline. The time courses of 
pixel changes from regions of interest were obtained and analyzed. 
Divided images were carefully examined to confirm activated re-
gions.
Triphenyl-tetrazolium chloride (TTC) staining and quanti-
fication of infarct volume
After ORIS, the brains of animals were removed from the head. 
The cerebrum was sectioned coronally into 6 pieces of 2 mm 
thickness. The sections of the cerebrum were immediately stained 
with a 2% triphenyl-tetrazolium chloride solution (TTC, sigma, 
US) in 6-well plates for 20 minutes. The sections were then trans-
ferred in paraformaldehyde (PFA). After 24 hours, each section 
was photographed and the infarction size was measured using the 
Image J (NIH, USA) software program.
Statistical analysis
A Mann-Whitney U test was performed for the group compari-
son and data were expressed as the means±standard error of the 
means (SEM). Statistical significance were indicated at one of three 
levels. *p<0.05, **p<0.01, ***p<0.001.
RESULTS
The effects HSA oral administration on cerebral blood vol-
ume (CBV) changes following sensory cortex stimulation in 
MCAO model
The effects of HSA oral administration on cerebral blood volume 
(CBV) change correspondingly following sensory cortex stimula-
tion in a MCAO model. After administrating HSA and saline for 
two weeks, the animals underwent ORIS sessions to assess the 
protective effects of HSA on ischemia. The changes in CBV were 
calculated by selecting 6x6 pixels of the region of interest (ROI) 
near the stimulating electrode on the sensory cortex. Average 
pixel values of ROIs were calculated from individual animals and 
plotted over the entire time course to examine the CBV changes 
following electrical stimulation. Each group had 7 animals and 
all CBV changes were averaged (Fig. 1A). CBV of the ipsilateral 
hemisphere of animals that were orally administered with HSA 
Fig. 1. Cerebral blood volume (CBV) changes of animals with oral gavage of HSA and saline. (A) CBV of ipsilateral hemisphere in an animal with oral 
gavage of HSA was increased gradually while the CBV of ipsilateral hemisphere in an animal with oral gavage of saline that was decreased dramatically. 
The CBV of HAS group (n=7) showed a gradual increase while the saline group exhibited a large decrease (Scale bar: 1 mm). (B) The Maximum CBV 
change in ipsilateral hemisphere of HSA group was significantly higher than saline groups.
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gradually increased following direct electrical stimulation while 
those of animals given saline decreased significantly (Fig. 1A). The 
maximum CBV change of the HSA group was significantly higher 
than that of the saline group (p-value=0.0006, Fig. 1B).
The effects HSA oral administration on infarct size, neuro-
logical scores and weight changes in a MCAO model
TTC staining of the individual brains demonstrated that the ip-
silateral hemisphere of animals given HSA had smaller infarction 
sizes than those given saline. In particular, animals on saline expe-
rienced severe atrophy compared to the treatment group. The cor-
tex of the ipsilateral hemispheres of animals on HSA was mostly 
conserved and thus showed the entire cortical shape, whereas the 
cortex of animal on saline almost disappeared (Fig. 2A). The HSA 
group also had significantly smaller infarct size of the cortex than 
the saline group (p-value=0.0013, Fig. 2B).
We graded the animals with modified neurological severity 
scores (mNSS) on days 1, 7 and 14 after MCAO. mNSS of animals 
with HSA administration was significantly lower than the saline 
group on days 1 (p-value=0.0006) and 7 (p-value=0.0175) after 
MCAO (Fig. 2C). However, on day 14 after MCAO, the albumin 
group graded higher scores. Since the weight of the albumin group 
increased more than the saline group, they were unable to suspend 
from the beam for a long time. 
We weighed all animals on alternating days after the MCAO. On 
the 2nd day after MCAO, the saline group had a drastic decline in 
weight, with the weight of the HSA group declining less than the 
saline group. Since then, the HSA group gained weight constantly 
and regularly while the saline group did not. The weight changes 
(%) in the two groups were significantly different until the 10th 
day (p-values: 4 days=0.0006, 6 days=0.0006, 8 days=0.00233, 10 
days=0.02622; Fig. 2D). After the 10th day, the difference between 
both groups became negligible.
DISCUSSION
Albumin therapy is known to reduce brain edema and improve 
local vascular perfusion. It acts similarly to an antioxidant and is 
more powerful than vitamin E [15], without any observable side 
effects in humans [7-9]. Additionally, albumin provides essential 
fatty acids to the injured brain [16, 17]. When albumin concentra-
tions in both plasma and interstitial fluids are high, the protein 
Fig. 2. Infarct size and mNSS, weight change of animals with oral gavage of HSA and saline. (A) TTC staining of the individual brain was shown that 
the ipsilateral hemisphere brain of an animal with oral gavage of HSA had smaller infarction than one of an animal with oral gavage of saline. (B) In av-
erage, HSA group (n=7) had smaller infarct size than saline group (n=7). (C) mNSS of HAS group (n=7) was lower than saline group (n=7) on 1 day and 
7 days after MCAO. (D) After MCAO, HSA group (n=7) gained the weight constantly and regularly. But saline group (n=7) lost more weight than HSA 
group.
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scavenge for radical oxygen and bind to free fatty acids and metal 
ions, thus obstructing the oxidative process of lipid peroxidation. 
Albumin can also inhibit copper-ion-dependent lipid peroxida-
tion binding to copper ions. Albumin can retard the formation 
of highly reactive hydroxyl radical species by acting as a multiple 
binding site that traps free radicals [18]. In functional association 
with changes in redox status, the structure and beneficial antioxi-
dant properties of albumin adjust accordingly. Albumin essentially 
constitutes the major plasmic target protein of oxidant stress [17]; 
it is the main target of reactive oxygen species (ROS) and may 
function to prevent oxidative damage by sequestering and reduc-
ing ROS in stroke models [19]. In addition, the ROS-sensitivity of 
albumin stems from its cysteine and methionine residues that have 
ROS-scavenging capacities [20]. These effects of albumin can thus 
improve reperfusion injuries in a stroke model. 
Transient ischemic stroke provokes the huge loss of phospho-
lipid-acyl groups. As such, albumin provides essential fatty acids 
like DHA, which can be a crucial element in facilitating neuronal 
membrane repair [3] and proper physical conformations of ion 
channels, receptors, transporters and neuroprotectin D1 (NPD1) 
precursors [9, 21, 22]. NPD1 is related to the reduction of neu-
roinflammation and activation of antiapoptotic pathways. Thus, 
albumin can provide protective effects to the ischemic brain.
Thus far, HSA is commonly injected intravenously to patients, 
including stroke patients [23]. Intravenous injections assuredly 
deliver materials into the vascular system, but it can be difficult in 
some situations such as in repeated and long term treatment. IV is 
an invasive method for drug medication due to its side effects such 
as infection [24]. On the other hand, oral administration can be 
easier than intravenous injections, especially if everyday treatment 
or preventive intervention are necessary. In addition, oral admin-
istration can be easily applied for long term medication. However, 
oral administration may have less availability for absorption to 
target sites unlike intravenous injections, such that high doses of 
HSA solution may be needed for MCAO models.
We found that oral administration of HSA has effects on cerebral 
perfusion and infarct size. We demonstrated that oral administra-
tion of HSA has neuroprotective effects on focal cerebral ischemia. 
MCAO animals with a two-week oral administration of HSA 
showed a different general spreading pattern and large maximum 
amplitude of cerebral blood volume (CBV) changes near the direct 
cortical stimulation site compared to the group given a control 
substance. In the normal cortex, direct electrical stimulation deliv-
ered into the cortical tissue results in notable subsequent increases 
in CBV along the ipsilateral hemisphere of the stimulation. In our 
previous study, the direct electrical stimulation caused dramatic 
reduction in CBV following electrical stimulation in the sensory 
cortex of animals MCAO. The MCAO animal with saline admin-
istration showed similar patterns with those from our previous 
study that were without any given treatment [13]. However, CBV 
changes of the albumin group exhibited gradual increases fol-
lowing direct electrical stimulation, suggesting that their cortical 
tissue is capable of perfusing cortical blood more than the saline 
group. In addition, the infarction size of animals that were orally 
administrated with HSA is significantly smaller than that of the 
saline group. The albumin group also showed minimal necrosis of 
the ipsilateral hemisphere whereas the saline group had drastic ne-
crosis due to MCAO. These results indicate that HSA may prevent 
neuronal apoptosis and conserve neuronal membranes from focal 
cerebral ischemia. We also found that a two-week oral administra-
tion of HSA improved neurological deficits caused by MCAO. 
In particular, from days 4 through 10 post-MCAO, the modified 
NSS of the albumin group was lower than that of the saline group, 
suggesting that HSA delivers protective effects on multiple levels 
of the neurosystem, including behavior and cortical perfusion. 
In fact, improved cortical perfusion may lead to better cognitive 
function. Lastly, the gradual and stable weight gain of the albumin 
group may also imply less stress from focal cerebral diseases than 
the saline group.
The question remains as to how HSA can affect neuronal damage 
after the process of digestion. HAS digestion is still not well under-
stood; it is however known to be divided at residue 307 to produce 
two fragments by limited pepsin digestion [25]. This degradation 
may result in greater exposure of the ligand domain that binds free 
fatty acids [20], which in turn protects neuronal cells [26]. In ad-
dition, the products from HSA degradation, such as amino acids, 
are harmless and can be preferentially taken in by damaged tissues 
for nutrition [27, 28]. Because of these properties of HSA, the pro-
tein can have beneficial effects at sites of inflammation, which are 
representative of the damages at focal ischemia in organ and cells 
[29, 30]. On the other hand, HSA that is not digested can circulate 
in the blood and act as neuroprotectants. Cortical neurons take 
up albumin directly when the blood-brain barrier is perturbed 
during focal ischemia. It has also been indicated that albumin may 
have neuroprotective effects through direct cellular uptake [31]. 
Given these evidence, oral administration of HSA may thus have 
neuroprotective effects following focal ischemia. Thus, our current 
study strongly suggest that a simple oral administration of HSA 
may have neuroprotective effects against focal cerebral ischemia in 
a MCAO animal model.
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